Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sotalol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 1.00 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 0.97 |
| ▸ | GLA | P06280 | 1/20 | 0.97 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MTOR | P42345 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexsotalol SCHEMBL203209 | 1.00 | ADRB3 (1.00) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL29761416 | 1.00 | ADRB3 (1.00) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL6508618 | 1.00 | ADRB3 (1.00) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL118761 | 0.98 | ADRB3 (1.00) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Dexsotalol SCHEMBL5661932 | 0.98 | ADRB3 (1.00) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL20575697 | 0.98 | ADRB3 (1.00) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL3127442 | 0.97 | ADRB3 (0.94) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL3287528 | 0.97 | ADRB3 (0.94) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL1649808 | 0.97 | ADRB3 (0.94) | ADRB3LMNAADRB2ADRB1MEN1 | |
| Sotalol SCHEMBL29188242 | 0.92 | ADRB3 (0.84) | ADRB3LMNAADRB2ADRB1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23975 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12622875-B2 | Dosage form comprising an alkaline agent and an enteric coating layer | EVONIK OPERATIONS GMBH (DE) | 2026-05-12 | — | — | US | claimed |
| US-20260124393-A1 | DOWN TITRATION LOADING OF SOTALOL INTRAVENOUSLY | ACAD PHARMACEUTICALS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12599567-B2 | Method for preparing a veterinary medicament dosage with inks and a veterinary medicament dosage obtainable by the method | CURIFYLABS OY (FI) | 2026-04-14 | — | — | US | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20260076953-A1 | METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-19 | — | — | US | claimed |
| EP-0105996-A1 | Ophthalmic compositions for treating elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-04-25 | — | — | EP | claimed |
| US-4428883-A | NASAL OINTMENTS OR GELS | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1984-01-31 | — | — | US | claimed |
| EP-0098113-A1 | A combination of beta-adrenoceptor antagonists and anxiolytic agents | AYERST, MCKENNA AND HARRISON INC. (CA) | 1984-01-11 | — | — | EP | claimed |
| EP-0085514-A2 | Compositions comprising a beta-antagonist and a beta-agonist, their preparation, and their use in treating obese humans and animals | BEECHAM GROUP PLC (GB) | 1983-08-10 | — | — | EP | claimed |
| EP-0073819-A1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR. | UNIV KENTUCKY RES FOUND (US) | 1983-03-16 | — | — | EP | claimed |
| EP-0069385-A2 | Use of eucalyptol for enhancing skin permeation of bioaffecting agents | MERCK & CO. INC. (US) | 1983-01-12 | — | — | EP | claimed |
| WO-1982003009-A1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR | UNIV KENTUCKY RES FOUND (US) | 1982-09-16 | — | — | WO | claimed |
| US-4311685-A | Assay method and kit | BURROUGHS WELLCOME CO. (US) | 1982-01-19 | — | — | US | claimed |
| US-4303637-A | Medication indicated for ocular hypertension | ALZA CORPORATION (US) | 1981-12-01 | — | — | US | claimed |
| US-4248853-A | FOR RAPID DETERMINATION OF ADRENERGIC BLOCKING AGENT IN PATIENTS BY MEASURING THE AMOUNT OF RADIOACTIVE BINDER ON THE RECEPTOR MATERIAL | Snyder, Solomon Halbert (US) | 1981-02-03 | — | — | US | claimed |